AR054808A1 - Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes - Google Patents

Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Info

Publication number
AR054808A1
AR054808A1 ARP060102810A ARP060102810A AR054808A1 AR 054808 A1 AR054808 A1 AR 054808A1 AR P060102810 A ARP060102810 A AR P060102810A AR P060102810 A ARP060102810 A AR P060102810A AR 054808 A1 AR054808 A1 AR 054808A1
Authority
AR
Argentina
Prior art keywords
derivative
compositions
iron oxide
coverage
acceptable
Prior art date
Application number
ARP060102810A
Other languages
English (en)
Inventor
Andreas Briel
Bernhard Gleich
Jurgen Weizenecker
Martin Rohrer
Hanns-Joachim Weinmann
Hubertus Pietsch
Ruediger Lawaczeck
Matthias Rother
Jens Thomsen
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR054808A1 publication Critical patent/AR054808A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/0515—Magnetic particle imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Complejos que contienen partículas magnéticas de oxido de hierro policristalino en una cobertura aceptable para uso farmacéutico, y al uso de dichas composiciones en el diagnostico por imágenes con partículas magnéticas (MPI). Se prefiere en particular el uso de dichas composiciones en exámenes del tracto gastrointestinal, del sistema vascular cardíaco y componentes craneanos, en el diagnostico de arteriosclerosis, infartos y tumores y metástasis, por ejemplo del sistema linfático. Reivindicacion 1: Una partícula caracterizada porque comprende, dentro de una cobertura aceptable para uso farmacéutico, un nucleo de oxido de hierro magnético policristalino con un diámetro entre 20 nm y 1 micron. Reivindicacion 3: Una partícula de acuerdo con la reivindicacion 1 o 2, caracterizada porque la cobertura aceptable para uso farmacéutico comprende un polímero o copolímero sintético, un almidon o un derivado del mismo, un dextrano o un derivado del mismo, un ciclodextrano o un derivado del mismo, un ácido graso, un polisacárido, una lecitina o un mono-, di- o triglicérido o un derivado del mismo o mezclas de los mismos. Reivindicacion 11:Un método para producir partículas que comprende, dentro de una cobertura aceptable para uso farmacéutico, un nucleo de oxido de hierro magnético policristalino con un diámetro entre 20 nm y 1micron, caracterizado porque dicho método comprende los siguientes pasos: ( i ) mezclar una solucion acuosa mixta de sales de hierro, que contiene una sal de hierro (II) y una sal de hierro (III), con una solucion alcalina acuosa en presencia de un polímero o copolímero sintético, un almidon o un derivado del mismo, un dextrano o un derivado del mismo, un ciclodextrano o un derivado del mismo, un ácido graso, un polisacárido, una lecitina o un mono-, di- o triglicérido o un derivado del mismo o mezclas de los mismos, hasta que se forma una suspension coloidal de las partículas, /ii) hacer pasar la solucion que contiene la partícula a través de un gradiente de campo magnético, (iii) quitar el gradiente de campo magnético, (iv) y recuperar las partículas retenidas en el gradiente de campo.
ARP060102810A 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes AR054808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014058A EP1738773A1 (de) 2005-06-29 2005-06-29 Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren

Publications (1)

Publication Number Publication Date
AR054808A1 true AR054808A1 (es) 2007-07-18

Family

ID=35432430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102810A AR054808A1 (es) 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Country Status (14)

Country Link
US (2) US20070014730A1 (es)
EP (2) EP1738773A1 (es)
JP (1) JP5366543B2 (es)
CN (1) CN101365495B (es)
AR (1) AR054808A1 (es)
BR (1) BRPI0611756A2 (es)
DO (1) DOP2006000154A (es)
GT (1) GT200600288A (es)
PA (1) PA8684201A1 (es)
PE (1) PE20070345A1 (es)
RU (1) RU2420319C2 (es)
TW (1) TW200800275A (es)
UY (1) UY29643A1 (es)
WO (1) WO2007000351A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren
CN104042214A (zh) * 2007-01-24 2014-09-17 皇家飞利浦电子股份有限公司 用于影响和/或探测作用区域中的磁性粒子的方法、磁性粒子以及磁性粒子的使用
JP2011516462A (ja) * 2008-04-03 2011-05-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 磁性粒子イメージング用生体適合物
CN102348994A (zh) 2009-03-09 2012-02-08 皇家飞利浦电子股份有限公司 用于测量作用区域中的磁性材料的设备和方法
KR101085824B1 (ko) * 2009-03-11 2011-11-23 한국유나이티드제약 주식회사 생체적합성 고분자를 이용한 다기능성 조영제 및 이의 제조방법
WO2010128418A1 (en) 2009-05-08 2010-11-11 Koninklijke Philips Electronics N.V. Arrangement and method for heating of a magnetic material
WO2011001351A1 (en) * 2009-07-01 2011-01-06 Koninklijke Philips Electronics N. V. Stimuli-responsive carriers for mpi-guided drug delivery
WO2011030271A1 (en) * 2009-09-14 2011-03-17 Koninklijke Philips Electronics N.V. Apparatus and method for moving and activating an active agent
WO2011163136A2 (en) * 2010-06-21 2011-12-29 University of Washington Center for Commercialization Tuned multifunctional magnetic nanoparticles for biomedicine
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
WO2012007871A1 (en) 2010-07-13 2012-01-19 Koninklijke Philips Electronics N.V. System and method for generating a system function for use in the reconstruction of images
RU2497546C1 (ru) * 2012-04-23 2013-11-10 Общество с ограниченной ответственностью "Ланда Фармасьютикалз" Магнитно-резонансное и рентгеновское контрастное средство и способ его получения
CN103316361B (zh) * 2013-07-08 2015-04-01 武汉百仕康生物科技有限公司 一种稳定的纳米级超顺磁氧化铁溶液及其制备方法和应用
CN103704232B (zh) * 2013-11-01 2016-01-06 北京科技大学 纳米农药羧甲基-β-环糊精-Fe3O4磁性纳米-敌草隆的制备方法
EP3081234B1 (en) * 2013-12-13 2020-04-08 Mercury Asset Management Co., Ltd. Articular cartilage imaging composition
US10898581B2 (en) * 2014-01-16 2021-01-26 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
JP2019151552A (ja) * 2016-07-12 2019-09-12 名糖産業株式会社 磁性粒子
KR20200017820A (ko) * 2018-08-09 2020-02-19 (주)아모레퍼시픽 미세먼지 제거용 다공성 복합분체 및 이의 제조방법
CN111298140B (zh) * 2020-03-24 2022-04-19 中国科学院苏州纳米技术与纳米仿生研究所 还原响应的t1/t2切换型mri造影剂、其制备方法及应用
CN115125537B (zh) * 2022-08-05 2023-04-11 四川轻化工大学 一种脱除聚晶金刚石复合片中钴的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102780A (en) * 1976-03-09 1978-07-25 S. G. Frantz Company, Inc. Method and apparatus for magnetic separation of particles in a fluid carrier
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
ATE179185T1 (de) * 1992-08-05 1999-05-15 Meito Sangyo Kk Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet
DE59403734D1 (de) * 1993-03-17 1997-09-18 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
RU2147243C1 (ru) * 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
DE19624426A1 (de) * 1996-06-19 1998-01-02 Christian Bergemann Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen
AU727764B2 (en) * 1996-08-05 2000-12-21 Schering Aktiengesellschaft Process for the production of contrast media for magnetic resonance tomography
DE69941689D1 (de) * 1998-02-12 2010-01-07 Univ Texas Verfahren und reagenzien zur raschen und effizienten isolierung zirkulierender krebszellen
GB9921579D0 (es) * 1999-09-13 1999-11-17 Nycomed Imaging As
AU4305101A (en) * 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10151778A1 (de) * 2001-10-19 2003-05-08 Philips Corp Intellectual Pty Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel
US9808173B2 (en) * 2003-04-15 2017-11-07 Koninklijke Philips N.V. Method for the spatially resolved determination of physcial, chemical and/or biological properties or state variables
JP4583370B2 (ja) * 2003-04-15 2010-11-17 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 検査領域内の磁性粒子の分布を空間分解して特定する方法
US7747304B2 (en) * 2003-04-15 2010-06-29 Koninklijke Philips Electronics N.V. Arrangement and method for the spatially resolved determination of state variables in an examination area
CN1882364A (zh) * 2003-11-17 2006-12-20 皇家飞利浦电子股份有限公司 用于医学成像技术的造影剂及其应用
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren

Also Published As

Publication number Publication date
WO2007000351A1 (en) 2007-01-04
EP1898960A1 (en) 2008-03-19
US20070014730A1 (en) 2007-01-18
CN101365495B (zh) 2013-09-04
DOP2006000154A (es) 2008-05-15
PE20070345A1 (es) 2007-04-20
PA8684201A1 (es) 2007-01-17
US20070036729A1 (en) 2007-02-15
EP1738773A1 (de) 2007-01-03
JP2008544968A (ja) 2008-12-11
CN101365495A (zh) 2009-02-11
TW200800275A (en) 2008-01-01
RU2420319C2 (ru) 2011-06-10
UY29643A1 (es) 2007-01-31
RU2008103203A (ru) 2009-08-10
JP5366543B2 (ja) 2013-12-11
GT200600288A (es) 2007-03-14
BRPI0611756A2 (pt) 2012-04-17

Similar Documents

Publication Publication Date Title
AR054808A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes
Abdukayum et al. Gadolinium complexes functionalized persistent luminescent nanoparticles as a multimodal probe for near-infrared luminescence and magnetic resonance imaging in vivo
AR054506A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes
Cheng et al. Polydopamine-coated manganese carbonate nanoparticles for amplified magnetic resonance imaging-guided photothermal therapy
Sánchez et al. Hybrid decorated core@ shell janus nanoparticles as a flexible platform for targeted multimodal molecular bioimaging of cancer
Xu et al. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood
Venerando et al. Magnetic nanoparticles with covalently bound self-assembled protein corona for advanced biomedical applications
Wang et al. Commercial nanoparticles for stem cell labeling and tracking
US20220404349A1 (en) Methods and uses for remotely triggered protease activity measurements
Yang et al. Carbon dots as nontoxic and high-performance fluorescence imaging agents
Freund et al. A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies
JP5174654B2 (ja) 官能基化された磁性ナノ粒子およびその使用法
Mehrmohammadi et al. In vivo pulsed magneto-motive ultrasound imaging using high-performance magnetoactive contrast nanoagents
US20110021745A1 (en) Ultra-small chitosan nanoparticles useful as bioimaging agents and methods of making same
AU2013303233C1 (en) Prostate specific antigen agents and methods of using same for prostate cancer imaging
Saladino et al. Optical and X-ray fluorescent nanoparticles for dual mode bioimaging
Tu et al. Multimodality PET/MRI agents targeted to activated macrophages
Yin et al. Folic acid-conjugated organically modified silica nanoparticles for enhanced targeted delivery in cancer cells and tumor in vivo
Kuo et al. AS1411 aptamer-conjugated Gd 2 O 3: Eu nanoparticles for target-specific computed tomography/magnetic resonance/fluorescence molecular imaging
Thakur et al. Poly-l-lysine-functionalized green-light-emitting carbon dots as a fluorescence turn-on sensor for ultrasensitive detection of endotoxin
Cai et al. Self-assembled hybrid nanocomposites for multimodal imaging-guided photothermal therapy of lymph node metastasis
Zhou et al. Mitochondria-localized self-reporting small-molecule-decorated theranostic agents for cancer-organelle transporting and imaging
Liu et al. Biocompatible KMnF3 nanoparticular contrast agent with proper plasma retention time for in vivo magnetic resonance imaging
AU2017203920B2 (en) Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
Dumych et al. Visualization of melanoma tumor with lectin-conjugated rare-earth doped fluoride nanocrystals

Legal Events

Date Code Title Description
FA Abandonment or withdrawal